Metrion Biosciences’ Business Manager Dr John Ridley, Head of Client Research Services, Dr Robert Kirby and Senior Scientist, Dr Edward Humphries will be attending, presenting posters and exhibiting at the Safety Pharmacology Society (SPS) Annual Meeting. The event is to be held at the Centre de Convencions Internacional de Barcelona between 23rd and 26th September 2019.
Metrion will be located at Booth # 203 in the exhibits hall for the duration of the event.
Metrion will be presenting two posters which will be displayed from 23rd to 25th September:
Poster 34: “Predicting Proarrhythmic Risk Exclusively Using Automated Patch Clamp Data” (presented by Dr Edd Humphries)
Poster 156: “Development of An Impedance Based Screening Assay for Cardiac Safety and Cardiotoxicity Detection” (presented by Dr John Ridley, Dr Edd Humphries and Dr Robert Kirby)
Please email email@example.com if you wish to arrange a meeting with one of our attendees.
Metrion Biosciences is a UK-based Contract Research Organization (CRO) located within the Cambridge bio cluster, one of Europe’s largest bioscience research hubs. Our state of the art laboratories at Granta Park house high quality facilities for native and engineered cell line and induced pluripotent stem cell culture, a comprehensive suite of automated patch clamp platforms, multiple manual patch clamp rigs, fluorescence-based screening capability and laboratory data management and reporting systems. Our company is focussed upon delivering a range of high quality ion channel drug discovery services. We provide highly skilled electrophysiology screening services to support client medicinal chemistry optimisation programmes, CiPA compliant cardiac safety profiling assays, neuroscience assays and translational assays. We combine in depth target class knowledge and high quality screening assays with highly experienced and collaborative drug discovery managers to keep your research focused upon meeting both objectives and timelines. Our team has successfully delivered many projects on behalf of our clients from once off screening projects to fully integrated drug discovery programmes delivering clinical candidates.